MedTrace Logo

Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome

NCT00391924 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2006-10-25

No results posted yet for this study

Summary

The purpose of the study is to examine whether dehydroepiandrosterone (DHEA) administration improves fatigue and general well-being in patients with systemic lupus erythematosus or primary Sjögren's syndrome

Conditions

  • Lupus Erythematosus, Systemic
  • Sjogren's Syndrome

Interventions

DRUG

Dehydroepiandrosterone

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER

  • Dutch Arthritis Association

    collaborator INDUSTRY

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Ronald HW Derksen, MD,PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Completion
2003-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00391924 on ClinicalTrials.gov